Wednesday, August 04, 2021 CCTG MYX1 (MCRN‐003): Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Descriptive Cost Analysis from the MCRN‐003/MYX1 single arm phase II trial The MCRN-003/MYX1 clinical trial was conducted collaboratively between the Canadian Myeloma Research Group (previously known as the Myeloma Canada Research Network) and the Canadian Cancer Trials Group. The trial evaluated a once-weekly carfilzomib dosing regimen, more convenient for patients and, as discussed in this manuscript, more cost-effective for the health care system. Dr. Christopher Venner from the Cross Cancer Institute in Edmonton was Study Chair. This secondary economic analysis was led by Dr. Bethany Monteith. Monteith BE, Venner CP, Cheung MC, Pater J, Shepherd L, Richardson H, Reece D, Gul E, Lalancette M, Castonguay V, Kukreti V, Tiedemann R, Phua C, Bhella S, Dudebout J, Sherry M, Yen H, Chen BE, Hay AE. A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma (ONLINE). Eur J Haematol n/a: 2021. https://onlinelibrary.wiley.com/doi/10.1111/ejh.13671
